Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Journal of Biological Response Modifiers|February 1, 1990
A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytesH Shau, V Isacescu, Y Ibayashi, et al.
Immunology Letters|August 1, 1996
Human thymocyte responsiveness to stem cell factor: synergy with interleukin-2 for the generation of NK/LAK cytotoxicityC H Uittenbogaart, I Schmidc, S Kiertscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1988
Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]M S Mitchell, R A Kempf, W Harel, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
A comparative study of intravenous versus intralymphatic interleukin-2, with assessment of effects of interleukin-2 on both peripheral blood and thoracic-duct lymphG Sarna, H Machleder, J Collins, et al.
Journal of Neuroscience Research|September 24, 1999
Differential expression of peroxiredoxin subtypes in human brain cell typesT A Sarafian, M A Verity, H V Vinters, et al.
Free Radical Biology & Medicine|January 1, 1997
Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stressesH Shau, A T Kim, C C Hedrick, et al.
Bulletin of the New York Academy of Medicine|January 1, 1989
Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanomaM S Mitchell, R A Kempf, W Harel, et al.
The Journal of Surgical Research|May 1, 1997
Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted ratsJ L Kakkis, B Ke, S Dawson, et al.
Pageof 6